Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Germany equities were higher at the close on Thursday, as gains in the Pharmaceuticals & Healthcare, Industrials and ...

Germany stocks were higher after the close on Thursday, as gains in the Pharmaceuticals & Healthcare, Industrials and ...

Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales ...

European stocks traded higher on Thursday as investors digested a slew of earnings and awaited the European Central Bank's ...

German stocks traded higher on Thursday as investors digested a slew of earnings and awaited an interest rate cut by the European ...

The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously ...